Stanley Smith, MD
Hospitalist · Newnan, GANPI 1396729463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 337 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$658
- Boehringer Ingelheim$534
- AbbVie$479
- Novo Nordisk$478
- Astellas Pharma US Inc$356
- GSK$337
- plus $3K from 39 others
What the payments were for
- Food & beverage$5,886100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,886 in reported general payments places this provider in the 95th percentile of 812 hospitalist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 366 | $261,901 |
| JanuviaSitagliptin Phosphate | 204 | $225,138 |
| OzempicSemaglutide | 183 | $213,468 |
| JardianceEmpagliflozin | 167 | $178,330 |
| MounjaroTirzepatide | 87 | $128,526 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 146 | $44,844 |
| FarxigaDapagliflozin Propanediol | 41 | $39,408 |
| XareltoRivaroxaban | 56 | $35,657 |
| MyrbetriqMirabegron | 45 | $27,006 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $20,990 |
| GemtesaVibegron | 32 | $16,132 |
| RayaldeeCalcifediol | 18 | $15,787 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $15,466 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 63 | $13,354 |
| LinzessLinaclotide | 12 | $12,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $190 | $261,901366 claims |
| MerckJanuvia | $11 | $225,138204 claims |
| Novo NordiskOzempic, Levemir | $478 | $219,824194 claims |
| Boehringer IngelheimJardiance | $534 | $178,330167 claims |
| Lilly USA, LLCMounjaro | $336 | $128,52687 claims |
| GSKArexvy, Shingrix, Trelegy Ellipta | $337 | $68,198225 claims |
| AstraZenecaFarxiga, Nexium | $658 | $48,49653 claims |
| Johnson & JohnsonXarelto | $193 | $35,65756 claims |
| Astellas Pharma US IncMyrbetriq | $356 | $27,00645 claims |
| AbbVieLinzess, Synthroid | $479 | $18,21880 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $90 | $16,13232 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $10,7981,186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 812 hospitalist providers in Georgia.
Other hospitalist in Newnan
- James SmithNewnan$5K
- Sri Krishna MukkamalaCumming$240K
- Annie ParkCanton$19K
- Philippa AmeneGainesville$11K
- Anna SikodGainesville$9K
- Emilio LacayoAtlanta$9K
- Mukesh KumarAtlanta$6K
- Alfred RathinamAthens$6K
- Amaka EzimoraAtlanta$6K
- Anum NiaziMacon$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.